View source for Template:Drug Development and Design

'''Thursday, June 3, 1:00 PM - 5:40 PM'''
;Drug Development and Design
;Kellas 104
'''Organizer/Presider: Jason Herr'''

1:00 Introductory Remarks

1:05 193 ''Discovering Drugs, Tools and Interesting Chemical Properties''. '''Steven R. LaPlante''', Boehringer Ingelheim (Canada) Ltd.

1:45 194 ''Novel 5-HT3 Receptor Modulators for the Potential Treatment of Irritable Bowel Syndrome''. '''David D. Manning1''', Christopher L. Cioffi1, Kristen N. Ryan1, Alexander Usyatinsky1, Kevin Fitzpatrick1, Carla Hassler1, Svetlana Dobritsa1, Cheng Guo1, Liaqat Masih1, Zhenjun Zhang1, Sok Hui Choo1, Jonathan D. Wierschke1, William G. Earley1, Peter R. Guzzo1, Marlene L. Cohen2, Amy S. Butler3, Catherine A. Brady3 and Nicholas M. Barnes3, (1)AMRI, (2)Creative Pharmacology Solutions LLC, (3)Celentyx Ltd.

2:25 195 ''Rethinking Natural Products in the Light of New Synthetic Methodologies''. '''Mark Behnke''', MLBehnke Consulting

3:05 Intermission

3:10 196 ''Drug Development and Design: Fundamental Concepts in Scaling from Milligrams to Kilograms''. '''Robert Norrie''', AMRI

3:50 197 ''Recent Development in Catalysis at BI''. '''Wenjun Tang''', Boehringer Ingelheim Pharmaceuticals Inc

4:30 Intermission

4:35 198 ''Optimization of the β5 Potency and Cellular Activity of a Series of Non-Covalent Dipeptide Inhibitors of the Human20S Proteasome Guided by X-ray Crystallography''. '''Christopher Blackburn''', Cynthia Barrett, Jonathan Blank, Nancy Bump, Frank Bruzzese, Larry Dick, Paul Fleming, Khris Garcia, Paul Hales, Lee Herman, Matt Jones, Jane Liu, Darshan Sappal, Mike Sintchak, Chris Tsu and Ken Gigstad, Millennium Pharmaceuticals, The Takeda Oncology Company

4:55 199 ''Antimicrobial and Antitumor Properties of Silver Carbene Complexes Encapsulated in Nanoparticles''. '''Wiley J. Youngs''', Amanda R. Knapp, Matthew J. Panzner and Claire A. Tessier, University of Akron

<s>5:15 200 ''Synthesis, Characterisation and In-Vitro Cytotoxic Activity of Some Ru(II) Complexes''. '''Sreekanth Thota'''1, Subhas Somalingappa Karki2 and Erik de Clercq3, (1)S.R. College of Pharmacy, (2)KLE Academy of Higher Education and Research, (3)Rega Institute of Medical Research</s> The final presentation was canceled, because Dr. Thota did not attend the meeting.

5:35 Concluding Remarks

[[Category:Program content]]